-transparent.png){kind=logo}
Twenty-five schizophrenic outpatient subjects in a depot neuroleptic discontinuation study received an amphetamine challenge approximately 6 weeks after their last dose. Only five of these showed greater than three-point increases in positive symptoms on the BPRS, and all five relapsed within 30 days of the challenge. The 20 with less than three-point increases in positive symptoms showed extremely variable stability, relapsing from 20- greater than 600 days after the challenge. Thus, increase in positive symptoms after amphetamine may identify a group at risk for rapid relapse after neuroleptic discontinuation, but lack of such a response gives little prognostic information.
B Angrist, and
E Peselow, and
M Rubinstein, and
A Wolkin, and
J Rotrosen
February 1982,
Biological psychiatry,
B Angrist, and
E Peselow, and
M Rubinstein, and
A Wolkin, and
J Rotrosen
December 1995,
Progress in neuro-psychopharmacology & biological psychiatry,
B Angrist, and
E Peselow, and
M Rubinstein, and
A Wolkin, and
J Rotrosen
July 1999,
The American journal of psychiatry,
B Angrist, and
E Peselow, and
M Rubinstein, and
A Wolkin, and
J Rotrosen
July 2004,
The American journal of psychiatry,
B Angrist, and
E Peselow, and
M Rubinstein, and
A Wolkin, and
J Rotrosen
October 2012,
The New England journal of medicine,
B Angrist, and
E Peselow, and
M Rubinstein, and
A Wolkin, and
J Rotrosen
November 2023,
Industrial psychiatry journal,
B Angrist, and
E Peselow, and
M Rubinstein, and
A Wolkin, and
J Rotrosen
January 1986,
Comprehensive psychiatry,
B Angrist, and
E Peselow, and
M Rubinstein, and
A Wolkin, and
J Rotrosen
January 1999,
Psychiatria polska,
B Angrist, and
E Peselow, and
M Rubinstein, and
A Wolkin, and
J Rotrosen
December 1986,
Nederlands tijdschrift voor geneeskunde,
B Angrist, and
E Peselow, and
M Rubinstein, and
A Wolkin, and
J Rotrosen
January 1982,
Psychopharmacology,
